C-terminal modification of angiotensin II created compound 12, a biased AT1R agonist that enhances heart contractility while minimizing blood pressure elevation through selective β-arrestin over Gαq signaling.
Heart boost, no BP riseCompound 12 strengthened heart contractions in rats while barely affecting blood pressure — separating beneficial from harmful angiotensin effects
What the researchers found
Compound 12 showed low Gαq/potent β-arrestin activity at AT1R, enhanced left ventricular ejection fraction with limited pressor response in normotensive rats, and accessed a unique deep allosteric pocket in molecular modeling.
Why it matters
Heart failure needs better drugs. A peptide that strengthens the failing heart without raising blood pressure addresses a critical unmet need.
How the study worked
Synthesis of AngII Phe8 analogs, in vitro Gαq and β-arrestin signaling profiling, in vivo hemodynamic assessment in normotensive rats, and molecular modeling of AT1R binding.
What this study cannot tell us
Preclinical rat data. Normotensive rats may respond differently than heart failure models. Long-term cardiac effects unknown.
How to read the evidence
Preclinical proof-of-concept with in vitro signaling and in vivo hemodynamic validation. Novel biased agonist with strong rationale.
When this study was published
Published in 2025.
The bigger picture
Biased agonism — selectively activating one signaling pathway over another — is a powerful drug design principle. Achieving it through peptide modification demonstrates the precision possible with peptide therapeutics.
Questions still open
- Would compound 12 improve cardiac function in heart failure models?
- Can the biased signaling be further optimized through additional modifications?
- What is the pharmacokinetic profile of compound 12?
Common questions
How can angiotensin strengthen the heart without raising blood pressure?
Could this treat heart failure?
Read the original research
Tunable Biased Signaling of the Angiotensin II Type 1 Receptor for Inotropy via C-Terminal Peptide Engineering and Allosteric Site Targeting.
Journal of medicinal chemistry, 69(3), 2063-2081
Citation
Hadjadj, Margot; Hassanzadeh, Malihe; Martel, Justin; Roy, Marie-Frédérique; Giguère, Hugo; Murza, Alexandre; Holleran, Brian J; Namkung, Yoon; Froehlich, Ulrike; Leduc, Richard; Auger-Messier, Mannix; Laporte, Stéphane A; Boudreault, Pierre-Luc. (2026). Tunable Biased Signaling of the Angiotensin II Type 1 Receptor for Inotropy via C-Terminal Peptide Engineering and Allosteric Site Targeting.. Journal of medicinal chemistry, 69(3), 2063-2081. https://doi.org/10.1021/acs.jmedchem.5c01259